Actionable genomic biomarker research is on the rise. These indicators, which include patterns of gene expression or DNA changes, facilitate development of cancer patient treatments by enhancing disease diagnosis and prognosis as well as tracking therapy efficacy. Multiomic analyses, combining methods including whole exome/genome sequencing (WES/WGS), transcriptome sequencing, human leukocyte antigen (HLA) typing, and single-cell sequencing, hold promise to identify actionable genomic biomarkers of the future.
Click here for free access to our latest coronavirus/COVID-19 research, commentary, and news.
Support nonprofit science journalism
Science’s extensive COVID-19 coverage is free to all readers. To support our nonprofit science journalism, please make a tax-deductible gift today.
Read all of the best Custom Publishing content from Science. Visit our Custom Publishing section for special collections, tech features, posters and more.